2. Search Result
Search Result
Results for "

DSS

" in MedChemExpress (MCE) Product Catalog:

50

Inhibitors & Agonists

3

Biochemical Assay Reagents

1

Peptides

10

Natural
Products

1

Isotope-Labeled Compounds

3

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W019543
    DSS Crosslinker
    4 Publications Verification

    		 ADC Linker Cancer
    DSS Crosslinker is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
    DSS Crosslinker
  • HY-116282
    Dextran sulfate sodium salt (MW 5000)
    2 Publications Verification

    DSS (MW 5000); DXS (MW 5000)

    		 HIV Apoptosis Infection Inflammation/Immunology
    Dextran sulfate sodium salt (MW 5000) is a polymer of anhydroglucose with a molecular weight of 5000. Dextran sulfate sodium salt (MW 5000) can be used to induce acute colitis and cause apoptosis of colonic epithelial cells in mice. The concentration dose used in the study was 5% (in feed, w/w). The sulfated polysaccharide dextran sulfate is also an effective inhibitor of HIV. Dextran sulfate sodium salt (MW 5000) can significantly inhibit HIV-1 replication at a concentration that does not significantly inhibit the blood coagulation process. Dextran sulfate sodium salt (MW 5000) protects MT-4 cells from HIV-1-induced cellular pathogenicity. Dextran sulfate-induced colitis can be inhibited by Puerarin (HY-N0145), Baicalein (HY-N0196), β-Caryophyllene (HY-N1415).
    Dextran sulfate sodium salt (MW 5000)
  • HY-116282A
    Dextran sulfate sodium salt (MW 4500-5500)

    DSS (MW 4500-5500); DXS (MW 4500-5500)

    		 HIV Apoptosis Infection Inflammation/Immunology
    Dextran sulfate sodium salt (MW 4500-5500) is a polymer of anhydroglucose with a molecular weight of 4500-5500. Dextran sulfate sodium salt (MW 4500-5500) can be used to induce acute colitis and cause apoptosis of colonic epithelial cells in mice. The recommended molecular weight in the study is 5000 (HY-116282) and the use concentration is 5% (in feed, W/W). The sulfated polysaccharide dextran sulfate is also an effective inhibitor of HIV. Dextran sulfate sodium salt (MW 4500-5500) can significantly inhibit HIV-1 replication at concentrations that do not significantly inhibit the blood coagulation process. Dextran sulfate sodium salt (MW 4500-5500) protects MT-4 cells from HIV-1-induced cellular pathogenicity. Dextran sulfate-induced colitis can be inhibited by Puerarin (HY-N0145), Baicalein (HY-N0196), β-Caryophyllene (HY-N1415).
    Dextran sulfate sodium salt (MW 4500-5500)
  • HY-116282B
    Dextran sulfate sodium salt (MW 16000-24000)
    2 Publications Verification

    DSS (MW 16000-24000); DXS (MW 16000-24000)

    		 Biochemical Assay Reagents Others
    Dextran sulfate sodium salt (MW 16000-24000) is a polymer of anhydroglucose with the molecular weight range of 16000-24000.
    Dextran sulfate sodium salt (MW 16000-24000)
  • HY-116282C
    Dextran sulfate sodium salt (MW 35000-45000)
    2 Publications Verification

    DSS (MW 35000-45000); DXS (MW 35000-45000)

    		 HIV Apoptosis Infection Inflammation/Immunology
    Dextran sulfate sodium salt (MW 35000-45000) is a polymer of anhydroglucose and is a potent inducer of colitis. Dextran sulfate sodium salt (MW 35000-45000) may be related to macrophage dysfunction, intestinal flora dysbiosis, and is particularly toxic to the colonic epithelium. Dextran sulfate sodium salt (MW 35000-45000) also inhibits human immunodeficiency virus replication by preventing viral adsorption to host cells. Dextran sulfate sodium salt (MW 35000-45000) is also used to bind to insulin, encapsulate it in gold nanoparticles, and serve as an insulin carrier to bind to insulin receptors to achieve the purpose of slowly releasing insulin and prolonging insulin activity .
    Dextran sulfate sodium salt (MW 35000-45000)
  • HY-116282D
    Dextran sulfate sodium salt (MW 450000-550000)

    DSS (MW 450000-550000); DXS (MW 450000-550000)

    		 HIV Apoptosis Others
    Dextran sulfate sodium salt (MW 450000-550000) is a polymer of anhydroglucose with a molecular weight range of 450000-550000. Dextran sulfate sodium salt (MW 450000-550000) can effectively enrich precipitated cells and can be used to isolate neutrophils from human and rat blood. Dextran sulfate sodium salt (average MW 500000) can effectively enhance the conversion activity of coagulation factor XIIa (FXIIa) to induce hepatocyte growth factor (HGF) and increase the specific activity of FXIIa.
    Dextran sulfate sodium salt (MW 450000-550000)
  • HY-147387
    DSS30

    		CDK Amyloid-β Inflammation/Immunology
    DSS30 is a P25/CDK5 inhibitor that reduces β-amyloid (Aβ) secretion by inhibiting amyloid precursor protein lyase 1 (BACEl) phosphorylation. DSS30 can be used in the study of neurodegenerative diseases such as Alzheimer's disease .
    DSS30
  • HY-W705390
    DSS Crosslinker-d4

    		Isotope-Labeled Compounds Others
    DSS Crosslinker-d4 is the deuterium labeled DSS Crosslinker. Radioactive isotopes labeled compounds can be used in metabolic analysis, allowing the movement of individual atoms to be precisely tracked and quantified .
    DSS Crosslinker-d4
  • HY-114766
    Pumafentrine

    		Phosphodiesterase (PDE) Inflammation/Immunology
    Pumafentrine is an orally active, potent dual PDE3/PDE4 inhibitor. Pumafentrine dose-dependently ameliorates the clinical score and colonic TNFα production in murine Dextran sulphate sodium (DSS; HY-116282C)-induced colitis in a preventive setting .
    Pumafentrine
  • HY-106275
    FX-06

    Fibrin-derived peptide Bβ15-42

    		 Flavivirus Dengue virus Cardiovascular Disease
    FX-06 (Fibrin-derived peptide Bβ15-42) is a fibrin Bbeta chain-derived peptide. FX-06 binds to VE-cadherin and inhibits leukocyte transmigration and initiates VE-cadherin-mediated signaling. FX-06 can be used in the research of ischemia/reperfusion injury, Dengue shock syndrome (DSS) .
    FX-06
  • HY-155199
    PDE1-IN-5

    		Phosphodiesterase (PDE) Inflammation/Immunology
    PDE1-IN-5 (Compound 10c) is a selective PDE1C inhibitor (IC50: 15 nM). PDE1-IN-5 has anti- inflammatory activity, and inhibits expression of iNOS, TNF-α, IL-1α, IL-1β, and IL-6 induced by LPS. PDE1-IN-5 has anti-inflammatory bowel disease (IBD) effects in the dextran sodium sulfate (DSS)-Induced colitis mice model. PDE1-IN-5 can be used for research of IBD .
    PDE1-IN-5
  • HY-N0648
    Monotropein

    		Others Inflammation/Immunology
    Monotropein is an iridoid glycoside isolated Morinda officinalis. Monotropein inhibits the expression of inflammatory mediators in dextran sulfate sodium (DSS)-induced colitis mouse model .
    Monotropein
  • HY-162030
    MMT3-72

    		JAK Infection Inflammation/Immunology Cancer
    MMT3-72 is a weak inhibitor of JAK1. MMT3-72 has superior efficacy and reduced p-STAT3 in DSS-induced colitis .
    MMT3-72
  • HY-118704
    P-2281

    		mTOR Inflammation/Immunology Cancer
    P-2281 is a mTOR inhibitor with anticancer and anti-inflammatory efficacies. P-2281 suppresses dextran sulfate sodium (DSS)-induced colitis by inhibiting T cell function and is efficacious in a murine model of human colitis .
    P-2281
  • HY-162013
    NLRP3-IN-26

    		NOD-like Receptor (NLR) Pyroptosis Inflammation/Immunology
    NLRP3-IN-26 (compound 15Z) is a NLRP3 inhibitor with the IC50 of 0.13 μM. NLRP3-IN-26 can be used for DSS-induced colitis model study .
    NLRP3-IN-26
  • HY-N0648R
    Monotropein (Standard)

    		Others Inflammation/Immunology
    Monotropein (Standard) is the analytical standard of Monotropein. This product is intended for research and analytical applications. Monotropein is an iridoid glycoside isolated Morinda officinalis. Monotropein inhibits the expression of inflammatory mediators in dextran sulfate sodium (DSS)-induced colitis mouse model .
    Monotropein (Standard)
  • HY-N0238
    Atractylodin
    1 Publications Verification

    Atractydin

    		 Others Infection Inflammation/Immunology
    Atractylodin (Atractydin) is an orally active active ingredient obtained from the rhizome of Atractylodes lancea and A. chinensis. Atractylodin is a natural insecticide. Atractylodin has anti-inflammatory activity .
    Atractylodin
  • HY-162661
    P2Y14R antagonist 2

    		P2Y Receptor Inflammation/Immunology
    P2Y14R antagonist 2 (compound 39) is a potent, selective and orally active P2Y14R antagonist with an IC50 value of 0.40 nM. P2Y14R antagonist 2 shows anti-inflammatory activity. P2Y14R antagonist 2 has the potential for the research of colitis .
    P2Y14R antagonist 2
  • HY-158404
    METTL3-IN-8

    		METTL3 Inflammation/Immunology
    METTL3-IN-8 (7460-0250) is a potent METTL3 inhibitor. METTL3-IN-8 strongly ameliorates DSS-induced colitis. METTL3-IN-8 can be used Inflammatory bowel disease (IBD) research .
    METTL3-IN-8
  • HY-157211
    Anti-inflammatory agent 66

    		NF-κB p38 MAPK Inflammation/Immunology
    Anti-inflammatory agent 66 (compound 8) is a pterostilbene derivative with anti-inflammatory activity. Anti-inflammatory agent 66 inhibits pro-inflammatory cytokines by blocking the LPS-induced NF-κB/MAPK signaling pathway and effectively alleviates DSS-induced acute colitis in mice .
    Anti-inflammatory agent 66
  • HY-161519
    PKM2 activator 7

    		Pyruvate Kinase Inflammation/Immunology
    PKM2 activator 7 (Compd B4) is a PKM2 activator with the AC50 of 0.144 μM. PKM2 activator 7 suppresses DSS (HY-116282C)-induced colitis by inhibiting T cell growth in mouse colitis model .
    PKM2 activator 7
  • HY-157939
    GPR183 antagonist-3

    		EBI2/GPR183 Inflammation/Immunology
    GPR183 antagonist-3 (compound 33) is an oral active GPR183 antagonist with the IC50 of 8.7 μM. GPR183 antagonist-3 displays strong in vitro antimigration and anti-inflammatory activity in monocytes, and improves the pathological symptoms of DSS-induced experimental colitis .
    GPR183 antagonist-3
  • HY-161343
    HDL-16

    		P2Y Receptor Necroptosis Inflammation/Immunology
    HDL-16 is a potent P2Y14R antagonist with an IC50 of 0.3095 nM. HDL-16 ameliorates DSS (HY-116282C)-induced colitis through suppressing necroptosis of intestinal epithelium cells (IECs) and protecting mucosal barrier function .
    HDL-16
  • HY-156025
    HCAR2 agonist 1

    		Others Inflammation/Immunology
    HCAR2 agonist 1 (Compound 9n) is a Gi protein-biased allosteric modulator of HCAR2. HCAR2 agonist 1 activates the Gi protein signaling pathway. HCAR2 agonist 1 shows anti-inflammatory effect, and reduces mRNA level of pro-inflammatory cytokine (TNF-α, IL-1β, IL-6, and MCP-1). HCAR2 agonist 1 enhances anti-inflammatory effects of orthosteric agonists in the mouse model of colitis .
    HCAR2 agonist 1
  • HY-158403
    METTL3-IN-7

    		METTL3 Inflammation/Immunology
    METTL3-IN-7 (F039-0002) is a potent METTL3 inhibitor. METTL3-IN-7 strongly ameliorates dextran sodium sulfate (DSS)-induced colitis. METTL3-IN-7 can be used Inflammatory bowel disease (IBD) research .
    METTL3-IN-7
  • HY-162901
    NLRP3-IN-48

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NLRP3-IN-48 is an NLRP3 inhibitor. NLRP3-IN-48 targets the NLRP3 protein, affecting the assembly of the NLRP3 inflammasome and thereby inhibiting its activation. NLRP3-IN-48 has anti-inflammatory activity in a mouse model of acute colitis induced by DSS .
    NLRP3-IN-48
  • HY-162317
    AMPK-IN-5

    		JAK p38 MAPK Infection
    AMPK-IN-5 (compound 7m) is a Osthole (HY-N0054) derivative, and blocks MAPK signal transduction by inhibiting the phosphorylation of JNK and p38, thereby inhibiting the release of inflammatory cytokines. AMPK-IN-5 reduce DSS-induced ulcerative colitis and LPS (HY-D1056)-induced acute lung injury .
    AMPK-IN-5
  • HY-151252
    NIC-0102

    		Proteasome NOD-like Receptor (NLR) Inflammation/Immunology
    NIC-0102 is an orally active proteasome inhibitor (pIC50=7.55) that specifically inhibits NLRP3 inflammatory vesicle activation. NIC-0102 shows potent anti-inflammatory effects in a model of dextran sulfate sodium (DSS)-induced ulcerative colitis. NIC-0102 also inhibits production of pro-IL-1β .
    NIC-0102
  • HY-155181
    hCES2-IN-1

    		Others Cancer
    hCES2-IN-1 (Compound 24) is a reversible and selective hCES2 inhibitor (IC50: 6.72 μM). hCES2-IN-1 reduces the level of hCES2 in living cells. hCES2-IN-1 is effective against Irinotecan (HY-16562)-induced delayed diarrhea and DSS-induced ulcerative colitis .
    hCES2-IN-1
  • HY-161620
    DW18134

    		IRAK Inflammation/Immunology
    DW18134 is an inhibitor for interleukin receptor-associated kinase 4 (IRAK 4) with an IC50 of 11.2 nM. DW18134 inhibits phosphorylation of IRAK4 and IKK, downregulates the secretion of TNF-α and IL-6. DW18134 attenuates the Lipopolysaccharides (HY-D1056)-induced peritonitis and DSS-induced colitis in mouse models, and protects the intestinal barrier function .
    DW18134
  • HY-161936
    Z21115

    		Phosphodiesterase (PDE) Inflammation/Immunology
    Z21115 is an orally active inhibitor for phosphodiesterase 4 (PDE4), that inhibits PDE4D7 with IC50 of 10.5 nM. Z21115 inhibits Lipopolysaccharide (HY-D1056)-induced expression of IL-6, TNF-α and iNOS. Z21115 exhibits anti-inflammatory activity in DSS (HY-116282)-induced mouse colitis models without significant toxicity (1 g/kg) .
    Z21115
  • HY-111662
    Fc 11a-2

    		NOD-like Receptor (NLR) Inflammation/Immunology
    Fc 11a-2, a benzimidazole compound, is an orally active and potent NLRP3 inflammasome inhibitor. Fc 11a-2 restrains the formation of NLRP3 inflammasome by inhibiting activation of caspase-1 and thus the activation of IL-1b/IL-18. Fc 11a-2 prevents the development of Dextran sulfate sodium (DSS; HY-116282C)-induced murine experimental colitis .
    Fc 11a-2
  • HY-158111
    NLRP3-IN-34

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NLRP3-IN-34 (Compound T10) is an inhibitor for NLRP3 inflammasome. NLRP3-IN-34 inhibits ROS production, NLRP3 inflammasome-dependent IL-1β production (IC50 is 0.48 μM in cells J774A.1), and inhibits pyroptosis. NLRP3-IN-34 exhibits anti-inflammatory activity against DSS-induced peritonitis .
    NLRP3-IN-34
  • HY-167706
    Diethyl-Lodoxamide

    		Others Inflammation/Immunology
    Diethyl-Lodoxamide is a highly potent GPR35 agonist with potential to inhibit inflammatory bowel disease. Diethyl-Lodoxamide activates GPR35 in humans, mice and rats, showing similar EC50 values. Diethyl-Lodoxamide can alleviate the clinical symptoms of DSS-induced inflammatory bowel disease in mouse models, and the effect is better than the traditional drug 5-ASA. The pharmaceutical properties of Diethyl-Lodoxamide have been optimized to better meet the requirements of drug design .
    Diethyl-Lodoxamide
  • HY-N0586A
    Norisoboldine hydrochloride

    (+)-Laurelliptine hydrochloride

    		 Adenosine Receptor Inflammation/Immunology
    Norisoboldine hydrochloride is an orally active natural aryl hydrocarbon receptor (AhR) agonist. Norisoboldine hydrochloride, as a major isoquinoline alkaloid present in Radix Linderae, can be used for the research of Rheumatoid arthritis and Ulcerative colitis .
    Norisoboldine hydrochloride
  • HY-N0586
    Norisoboldine

    (+)-Laurelliptine

    		 Adenosine Receptor Inflammation/Immunology
    Norisoboldine is an orally active natural aryl hydrocarbon receptor (AhR) agonist. Norisoboldine, as a major isoquinoline alkaloid present in Radix Linderae, can be used for the research of Rheumatoid arthritis and Ulcerative colitis .
    Norisoboldine
  • HY-155998
    NF-κB-IN-11

    		NF-κB Inflammation/Immunology
    NF-κB-IN-11 (Compound 3i) is a NF-κB inhibitor. NF-κB-IN-11 inhibits TNF-α induced activation of NF-κB pathway, and inhibits nuclear translocation of NF-κB. NF-κB-IN-11 down-regulates the expression levels of phosphor-IKK, IκBα, and NF-κB p65. NF-κB-IN-11 has anti-inflammatory activity, and alleviates dextran sulfate sodium-induced colitis in mice. NF-κB-IN-11 (p.o.) shows a MTD more than 1852 mg/kg in mice acute toxicity assay .
    NF-κB-IN-11
  • HY-N0586R
    Norisoboldine (Standard)

    		Adenosine Receptor Inflammation/Immunology
    Norisoboldine (Standard) is the analytical standard of Norisoboldine. This product is intended for research and analytical applications. Norisoboldine is an orally active natural aryl hydrocarbon receptor (AhR) agonist. Norisoboldine, as a major isoquinoline alkaloid present in Radix Linderae, can be used for the research of Rheumatoid arthritis and Ulcerative colitis .
    Norisoboldine (Standard)
  • HY-N13174
    Peanut procyanidin A

    		Reactive Oxygen Species Apoptosis Inflammation/Immunology
    Peanut procyanidin A is a type of A-type procyanidin that can be extracted from peanut skins. Peanut procyanidin A can protect prostate DU145 cells from H2O2-induced oxidative stress damage through the MAPKs signaling pathway, alleviate cell cycle arrest, and reduce cell apoptosis. Peanut procyanidin A can also regulate gut microbiota and metabolism in mice with DSS (HY-116282)-induced ulcerative colitis .
    Peanut procyanidin A
  • HY-149365
    SIKs-IN-1

    		Salt-inducible Kinase (SIK) Inflammation/Immunology
    SIKs-IN-1 (compound 8h), a pyrimidine-5-carboxamide derivative, is a Salt-inducible kinases (SIKs) inhibitor. SIKs regulates the transformation of M1/M2 macrophages, involving in inflammation process. SIKs-IN-1 inhibits SIK activity, up-regulates anti-inflammatory cytokine IL-10, but down-regulates pro-inflammatory cytokine IL-12. SIKs-IN-1 shows excellent anti-inflammatory effects in a DSS-induced colitis model .
    SIKs-IN-1
  • HY-164670
    D228

    		Others Inflammation/Immunology
    D228 is an orally active antiinflammatory agent. D228 reduces ConA induced T lymphocyte cell proliferation (IC50: 42.85 μM) and LPS induced B lymphocyte cell proliferation (IC50: 3.15 μM). D228 is effective against inflammatory bowel disease (IBD). D228 alleviates the DSS (HY-116282C)-induced inflammation response in the IBD model by downregulating the MyD88/TRAF6/p38 signaling .
    D228
  • HY-158434
    IRAK1-IN-1

    		IRAK Inflammation/Immunology
    IRAK1-IN-1 (compound B8) is an orally active IRAK1 inhibitor. IRAK1-IN-1 inhibits the release of IL-6 with the IC50 values of 4.57 μM and 6.51 μM on mouse cells J774A. 1 and human cells THP-1, respectively. IRAK1-IN-1 alleviats LPS (HY-D1056)-induced acute lung injury (ALI) and DSS(HY-116282C)-induced colitis in mice .
    IRAK1-IN-1
  • HY-W042416
    N,N-Dimethylacetamide
    1 Publications Verification

    DMAc

    		 NF-κB Neurological Disease Metabolic Disease Inflammation/Immunology
    N,N-Dimethylacetamide (DMAc) is an organic solvent with blood-brain transmissibility and an FDA-approved drug excipient. N, N-dimethylacetamide exerts anti-inflammatory activity by inhibiting the NF-κB signaling pathway. N, N-dimethylacetamide can be used in studies of weight gain caused by a high-fat diet and neuroinflammation in Alzheimer's disease .
    N,N-Dimethylacetamide
  • HY-W042416R
    N,N-Dimethylacetamide (Standard)

    		NF-κB Neurological Disease Metabolic Disease Inflammation/Immunology
    N,N-Dimethylacetamide (Standard) is the analytical standard of N,N-Dimethylacetamide. This product is intended for research and analytical applications. N,N-Dimethylacetamide (DMAc) is an organic solvent with blood-brain transmissibility and an FDA-approved drug excipient. N, N-dimethylacetamide exerts anti-inflammatory activity by inhibiting the NF-κB signaling pathway. N, N-dimethylacetamide can be used in studies of weight gain caused by a high-fat diet and neuroinflammation in Alzheimer's disease .
    N,N-Dimethylacetamide (Standard)
  • HY-161627
    Anemoside A3-methyl 6-aminohexanoate

    		NF-κB Inflammation/Immunology
    Anemoside A3-methyl 6-aminohexanoate (Compound A3-6) is a derivative of Pulchinenoside C (Anemoside B4) (HY-N0205). Anemoside A3-methyl 6-aminohexanoate inhibits pyruvate carboxylase (PC) with an IC50 of 0.058 μM, reprograms macrophage function, and alleviates DSS-induced colitis through inhibition of the NF-κB and NLRP3 inflammasome pathway. Anemoside A3-methyl 6-aminohexanoate exhibits a moderate in vivo pharmacokinetic characters compared with Anemoside B4 .
    Anemoside A3-methyl 6-aminohexanoate
  • HY-N1934
    Dihydroberberine

    		Potassium Channel HSP Cardiovascular Disease Inflammation/Immunology Cancer
    Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy .
    Dihydroberberine
  • HY-162641
    AF-45

    		IRAK NF-κB p38 MAPK TNF Receptor Inflammation/Immunology
    AF-45 inhibits IRAK4 and IRAK1, with IC50s of 128 nM and 1765 nM. AF-45 inhibits the release of IL-6 and TNF-α in macrophages, with IC50s of 0.53-1.54 μM and 0.6-2.75 μM. AF-45 is also an inhibitor for NF-κB/MAPK signaling pathway. AF-45 exhibits anti-inflammatory activities against DSS-induced ulcerative colitis and Lipopolysaccharide (HY-D1056)-induced acute lung injury in mouse model. AF-45 exhibits good pharmacokinetic characteristics in rat models .
    AF-45
  • HY-159179
    α4 integrin receptor antagonist 3

    		Integrin Inflammation/Immunology
    α4 integrin receptor antagonist 3 (Compound 11) is an orally active α4integrin receptor antagonist. α4 integrin receptor antagonist 3 can inhibit the adhesion of K562 cells mediated by the interaction between α4β1/VCAM-1 and α4β7/MAdCAM-1, with IC50 values of 130 nM and 2 nM, respectively. α4 integrin receptor antagonist 3 has the potential to be used in the study of dextran sulfate sodium (DSS) colitis mouse model .
    α4 integrin receptor antagonist 3
  • HY-N1934R
    Dihydroberberine (Standard)

    		Potassium Channel HSP Cardiovascular Disease Inflammation/Immunology Cancer
    Dihydroberberine (Standard) is the analytical standard of Dihydroberberine. This product is intended for research and analytical applications. Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy .
    Dihydroberberine (Standard)
  • HY-N0847
    Micheliolide
    4 Publications Verification

    		 NF-κB PI3K Akt TGF-beta/Smad Inflammation/Immunology Cancer
    Micheliolide is a sesquiterpene lactone with anti-cancer and anti-inflammatory effects, which is derived from Michelia compressa and Michelia champaca. Micheliolide can attenuate high glucose-stimulated NF-κB activation, IκBα degradation, and the expression of MCP-1, TGF-β1, and FN in mouse mesangial cells. Micheliolide inhibits LPS (HY-D1056)-induced activation of NF-κB and PI3K/Akt/p70S6K pathways to play an anti-inflammatory role. Micheliolide inhibits dextran sodium sulphate (DSS) (HY-116282)-induced inflammatory intestinal disease, colitis-associated cancer and rheumatic arthritis .
    Micheliolide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: